Resources for Health Professionals
Examples of several of the most commonly used treatments are provided in the table below. As always, treatment decisions should be individualized.
|Drug*||Dosage regimen for adults|
|Iodoquinol||650 mg orally three times daily for 20 days|
|Paromomycin||25–35 mg per kg per day orally, in three divided doses, for 7 days|
|Metronidazole**||500–750 mg orally three times daily for 10 days|
*Not FDA-approved for this indication.
** Metronidazole is a nitroimidazole drug. The nitroimidazole drugs secnidazole and ornidazole have been used to treat D. fragilis infection but are unavailable in the United States.
Iodoquinol is available for human use in the United States.
Oral paromomycin is available for human use in the United States.
Metronidazole is available for human use in the United States.
- Stark D, Barratt J, Roberts T, et al. A review of the clinical presentation of dientamoebiasis. Am J Trop Med Hyg 2010;82:614–9.
- Kurt O, Girginkardesler N, Balcioglu IC, et al. A comparison of metronidazole and single-dose ornidazole for the treatment of dientamoebiasis. Clin Microbiol Infect 2008;14:601–4.
- Vandenberg O, Souayah H, Mouchet F, et al. Treatment of Dientamoeba fragilis infection with paromomycin. Pediatr Infect Dis J 2007;26:88–90.
- Vandenberg O, Peek R, Souayah H, et al. Clinical and microbiological features of dientamoebiasis in patients suspected of suffering from a parasitic gastrointestinal illness: a comparison of Dientamoeba fragilis and Giardia lamblia infections. Int J Infect Dis 2006;10:255–61.
- Girginkardesler N, Coskun S, Balcioglu IC, et al. Dientamoeba fragilis, a neglected cause of diarrhea, successfully treated with secnidazole. Clin Microbiol Infect 2003;9:110–3.
- Norberg A, Nord CE, Evengard B. Dientamoeba fragilis—a protozoal infection which may cause severe bowel distress. Clin Microbiol Infect 2003;9:65–8.
- Preiss U, Ockert G, Broemme S, et al. On the clinical importance of Dientamoeba fragilis infections in childhood. J Hyg Epidemiol Microbiol Immunol 1991;35:27-34.
This information is provided as an informational resource for licensed health care providers as guidance only. It is not intended as a substitute for professional judgment.
Oral iodoquinol has not been assigned a pregnancy category by the Food and Drug Administration. Data on the use of iodoquinol in pregnant women are limited, and risk to the embryo-fetus is unknown. Iodoquinol should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.
It is not known whether iodoquinol is excreted in breast milk. Iodoquinol should be used with caution in breastfeeding women.
The safety of iodoquinol in children has not been established.
Oral paromomycin has not been assigned to a pregnancy category by the Food and Drug Administration. Data on the use of oral paromomycin in pregnant women are limited, and the risk to the embryo-fetus probably is low. Oral paromomycin generally is poorly absorbed from the gastrointestinal tract, with minimal, if any, systemic availability.
Oral paromomycin is unlikely to be excreted in breast milk, and the drug generally is poorly absorbed from the gastrointestinal tract.
The safety of oral paromomycin in children has not been formally evaluated. However, the safety profiles likely are comparable in children and adults.
Metronidazole is in pregnancy category B. Data on the use of metronidazole in pregnant women are conflicting. The available evidence suggests use during pregnancy has a low risk of congenital anomalies. Metronidazole may be used during pregnancy in those patients who will clearly benefit from the drug, although its use should be weighed against any potential risks.
Pregnancy Category B: Either animal-reproduction studies have not demonstrated a fetal risk but there are no controlled studies in pregnant women or animal-reproduction studies have shown an adverse effect (other than a decrease in fertility) that was not confirmed in controlled studies in women in the first trimester (and there is no evidence of a risk in later trimesters).
Metronidazole is excreted in breast milk. The American Academy of Pediatrics classifies metronidazole as a drug for which the effect on nursing infants is unknown but may be of concern. The World Health Organization (WHO) advises to avoid metronidazole treatment in lactating women. Metronidazole should be used during lactation only if the potential benefit of therapy to the mother justifies the potential risk to the infant.
The safety of metronidazole in children has not been established. Metronidazole is listed as an antiamebic and antigiardiasis medicine on the WHO Model List of Essential Medicines for Children, intended for the use of children up to 12 years of age.